BusinessRitter Pharmaceuticals Selects Medpace as its Clinical Research Organization for Pivotal Phase 3 Clinical Trial of RP-G28 in Lactose IntoleranceBy Nasdaq OMXMay 3, 2018, 10:00 AM UTC
BusinessRitter Pharmaceuticals Announces 1-for-10 Reverse Stock SplitBy Nasdaq OMXMar 22, 2018, 3:35 PM UTC
BusinessRitter Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business UpdateBy Nasdaq OMXMar 19, 2018, 10:35 AM UTC
BusinessRitter Pharmaceuticals, Inc.’s Board Approves 1-for-10 Reverse Stock SplitBy Nasdaq OMXMar 1, 2018, 9:20 PM UTC
BusinessRitter Pharmaceuticals Appoints Diane J. Plotkin as Vice President of Clinical Development, Ahead of the Launch of its Phase 3 Clinical TrialBy Nasdaq OMXJan 29, 2018, 2:01 PM UTC
